Development and validation of GC/MS method for determination of pramipexole in rat plasma

Biomedical Chromatography

Volumn 25, Issue 4, 2011, Pages 524-530

  Panchal, Jayesh G ^a   Patel, Ravindra V ^a   Menon, Shobhana K ^a  

^a GUJARAT UNIVERSITY   (India)

Author keywords

Bio analytical; Gas chromatography mass spectrometry; Pharmacokinetic; Plasma; Pramipexole

Indexed keywords

BODY FLUIDS; GAS CHROMATOGRAPHY; IMPACT IONIZATION; IONIZATION OF GASES; MASS SPECTROMETRY; PHARMACOKINETICS; RATS;

ALKALINES; BIO-ANALYTICAL; GASCHROMATOGRAPHY-MASS SPECTROMETRY; LC-MS-MS; LOWER LIMIT OF QUANTIFICATIONS; PRAMIPEXOLE; RAPID METHOD; RAT PLASMA; SENSITIVE METHOD; SIMPLE METHOD;

SODIUM HYDROXIDE;

PRAMIPEXOLE; SODIUM HYDROXIDE; TERT BUTYL METHYL ETHER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; GAS CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUADRUPOLE MASS SPECTROMETRY; RAT; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; VALIDATION PROCESS;

RATTUS;

EID: 79952208267     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1478     Document Type: Article

References (22)

1. FDA. Guidance for Industry. Bioanalytical Method Validation. US Department of Health and Human Services, FDA, CDER, CVM, 2001; available at.
2. Gu M, Irvani M, Cooper JM, King D, Jenner P and Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. Journal of Neurochemistry 2004; 91: 1075-1081.
3. Gurupadayya BM, Vishwajith V and Srujana N. Spectrophotometric methods for the estimation of pramipexole dihydrochloride in pharmaceutical formulations. World Journal of Chemistry 2009; 4(2): 157-160.
4. Jama L, Hirvonen K, Partinen M, Alakuijala A, Hublin C, Tamminen I. Koester J and Reess J. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Medicine 2009; 10(6): 630-636.
5. Jancic B, Medenica M, Ivanovic D and Malenovic A. Experimental design in chromatographic analysis of pramipexole and its impurities. Acta Chimica Slovenica 2007a; 54: 49-54.
6. Jancic B, Medenica M, Ivanovic D and Malenovic A. Chromatographic determination of dissociation constants of pramipexole and its impurities. Chromatographia 2007b; 65: 633-635.
7. Kolster KS and Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. Neuropsychobiology 2004; 50: 65-70.
8. Lau YY, Selenka JM, Hanson GD, Talaat R and Ichhpurani N. Determination of pramipexole (U-98, 528) in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Journal of. Chromatography B 1996 a; 683: 209-216.
9. Lau YY, Hanson GD and Ichhpurani N. Determination of pramipexole (U-98, 528) in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection. Journal of. Chromatography B 1996 b; 683: 217-223.
10. Leentjens FG, Koester J, Fruh B, Toby D, Shephard S, Barone P and Houben JG. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clinical Therapeutics 2009; 31(1): 89-98.
11. Ling ZD, Robbie HC, Tong CW and Carve PM. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. Journal of Pharmacology and Experimental Therapeutics 1999; 289: 202-210.
12. Matuszewski B. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. Journal of Chromatography B 2006; 830: 293-300
13. Matuszewski B, Constanzer M and Chavez-Eng C. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
14. Musengaa A, Kenndlerb E, Morgantia E, Rasic F and Raggia MA. Analysis of the anti-Parkinson drug pramipexole in human urine by capillary electrophoresis with laser-induced fluorescence detection. Analytica Chimica Acta 2008; 626(1): 89-96.
15. Nirogi RVS, Kandikere V, Shrivastava W, Mudigonda K, Maurya S and Ajjala D. Quantification of pramipexole in human plasma by liquid chromatography tandem mass spectrometry using tamsulosin as internal standard. Biomedical Chromatography 2007; 21(11): 1151-1158.
16. Pan T, Xie W, Jankovic J and Le W. Biological effects of pramipexole on dopaminergic neuron associated genes: a relevance to neuroprotection. Neuroscience Letters 2005; 377: 106-109.
17. Partinen M, Hirvonen K, Jama L, Alakuijala A, Hublin C, Tamminen I, Koester J and Reess J. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study. Sleep Medicine 2006; 7(5): 407-417.
18. Pathare DB, Jadhav AS and Shingare MS. Validated chiral liquid chromatographic method for the enantiomeric separation of pramipexole dihydrochloride monohydrate. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 1152-1156.
19. Piercey MF, Hoffmann WE, Smith MW and Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. European Journal of Pharmacology 1996; 312: 35-44.
20. Pogarell O, Gasser T, Van-Hilten JJ, Spieker S, Pollentier S, Meier D and Oertel W. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Journal of Neurology, Neurosurgery and Psychiatry 2002; 72(6): 713-720.
21. Ramirez AD, Wong SK, and Menniti FS. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. European Journal of Pharmacology 2003; 475: 29-35.
22. Srinubabu G, Jaganbabu K, Sudharani B, Venugopal K, Girizasankar G and Rao JVLNS Development and validation of a LC method for the determination of pramipexole using an experimental design. Chromatographia 2006; 64(1/2): 95-100.